MEDICAL RECORD 
CONTINUATION SHEET for either: 
NIH 2514-1, Consent to Participate In A Clinical Research Study 
NIH 2514-2, Minor Patient’s Assent to Participate In A Clinical Research Study 
UDY NUMBER: CONTINUATION: page _9__ of ± 2 _ pages.) 
determine if your bone marrow continues to recover. After the 
first year you will be followed at NIH at least twice a year 
for five years. 
9) Interferon Treatment: Once your bone marrow has recovered 
and your blood counts are close to the normal, you will be 
started on a medicine called alpha-interferon that is given as 
an injection under the skin 3-7 times a week. This medicine 
has been shown to prolong remissions in myeloma patients 
treated with standard chemotherapy, and we think that it might 
help prevent relapse after bone marrow transplant. However, 
this is an experimental use for this medicine, and we do not 
know if it will prolong your survival or improve your chances 
of a cure. The side effects of alpha-interferon include 
fevers, muscle aching, fatigue, and low blood counts. We will 
continue you on the alpha-interferon for two years if you 
remain in remission. It will be stopped if you relapse or if 
* its side effects are not tolerable. 
If you are a woman of child-bearing age you will have a 
pregnancy test and if you are pregnant we will not include you 
in this study because to do so might be harmful to your unborn 
baby. We also want you to avoid getting pregnant during this 
study and expect you *to use an effective method of birth 
control. If you should become pregnant in spite of taking 
precautions piease contact the primary investigator whose 
phone number is listed in this form and she will discuss with 
you the choices that are available for you to consider. The 
radiation and. chemotherapy treatments given as a part of this 
protocol are very likely to make both men and women sterile or 
at a higher risk of bearing children with birth defects. 
BENEFITS : Potential benefits of this treatment plan included 
prolonged remission from your multiple myeloma. It is not yet 
known whether this type of treatment can cure your disease. 
It is also not yet known if this type of treatment will 
prolong your life. This treatment is a new approach that has 
not been carried out in enough patients to be sure about its 
effectiveness.lt may have unpredictable side effects that we 
have not described in this consent form. You will also be 
aiding medical science and society at large as this study may 
greatly further the understanding of the best method to 
successfully fight and' cure cancer. We cannot, however, 
guarantee that you will receive any of these benefits and at 
PATIENT IDENTIFICATION 
[ 78 ] 
CONTINUATION SHEET for either: 
NIH-2S14-1 MO-341 
Recombinant DNA Research, Volume 16 
I 
I 
i 
! 
